M
usculoskeletal disorders are well-recognized extraintestinal manifestations (EIM) of inflammatory bowel diseases (IBD). A similar etiopathogenesis has been postulated, based on genetic and immunological data. [1] [2] [3] [4] The prevalence of inflammatory articular disease (IAD) in patients with IBD has been reported somewhere between 10% and 45%, [5] [6] [7] reflecting possible differences in study design and patient selection. 5, [8] [9] [10] The pathogenic link between articular involvement and IBD is not yet fully understood. Some authors claim that the intestinal permeability may be higher both in patients suffering from IBD 11 and from spondyloarthropathies. 12 Several studies have demonstrated minimal or infraclinical digestive inflammation in patients with spondyloarthropathies or ankylosing spondylitis. [13] [14] [15] [16] Crohn's disease (CD) and spondyloarthropathies may be a similar immune-mediated inflammatory disease with distinct phenotypes and different clinical, immunological, histopathological, and genetic findings. 3, [16] [17] [18] Other common pathogenic pathways may involve the microbiome and distinct set of adhesion molecules. 19, 20 The aim of this study was to investigate the prevalence of IAD in a large multicentric cohort of well-characterized patients with IBD living in Switzerland, and to identify disease characteristics associated with the occurrence of IAD in patients with IBD.
MATERIALS AND METHODS

Patients' Population
The Swiss IBD Cohort Study was initiated by the IBDnet, an interest group of the Swiss Society of Gastroenterology in collaboration with the five Swiss University centers and funded by the Swiss National Science Foundation since 2006 (www.ibdnet.ch). All local ethics committees approved the study. The study is described in detail elsewhere. 21 Briefly, patients were enrolled by gastroenterologists in university hospitals, regional hospitals, and private practices. Diagnosis of IBD was based on Lennard-Jones criteria 22 and was supported by endoscopic, radiological, or histological/surgical findings. 21 To be included, a diagnosis of IBD had to be established at least 4 months before the inclusion or the patients must have had at least one recurrence of symptoms. It is estimated that about 25% of all Swiss patients with IBD were enrolled up to 2013. 23 The cohort appears to be representative of the Swiss IBD population as the same likelihood to be enrolled in the cohort was observed between regions. 23 Patients included in the present analysis were adults enrolled between July 2006 and December 2012. We excluded patients who did not complete the questionnaire.
Two distinct questionnaires were used to collect information at the time of patients' inclusion: one was completed by the physicianincluding disease characteristics and EIM-and one was completed by the patients. The patient self-reported questionnaire contained a set of questions on arthritides (see Questionnaire, Supplemental Digital Content 1, http://links.lww.com/IBD/B21). To validate our articular patient questionnaire, we administered the instrument to a control population of patients coming for a screening colonoscopy. In this group of 61 patients (mean age: 51.5 yrs, 59% male, 41% female), 67% reported some arthralgias, but only 13% fulfilled the criteria for IAD. These results suggest that the patient questionnaire is able to discriminate common arthralgias from IAD. As expected, the prevalence of self-reported arthralgias was fairly high in this elderly population. The "false-positive rate" of around 10% may be in part explained by some inflammatory presentations of osteoarthritis and by difficulties of some patients to qualify precisely their pain.
Outcome Variable
The outcome of interest for this analysis was the presence or absence of IAD in patients with IBD. IAD associated with IBD have been described and categorized using various criteria by different medical specialists. 5, 24, 25 Based on the clinical presentation, Orchard et al 5 have proposed a classification for peripheral IAD manifestations in 1998, distinguishing a pauciarticular flarelinked manifestation (type 1) and a polyarticular chronic manifestation (type 2). More recently, a consensus definition has proposed to regroup the articular manifestations of a group of interrelated conditions comprising ankylosing spondylitis, psoriasis, IBD, and reactive arthritis into axial and peripheral articular disease. 26, 27 In this study, we defined patients with IAD according to either (1) having had a documented episode of arthritis, confirmed by the gastroenterologist who included the patient or (2) fulfilling inflammatory pattern of pain on the patient questionnaire. An inflammatory pattern of joint pain was assessed as persistent or recurrent joint pain, associated with night pain, relief on movement, and morning stiffness lasting at least 30 minutes, based on published criteria. [26] [27] [28] [29] To assess the robustness of our IAD definition, we performed a sensitivity analysis with a strict IAD definition relying exclusively on the physician-reported IAD. We categorized IAD in 2 subgroups: (1) pure peripheral articular disease and (2) IAD with axial involvement, with or without peripheral arthritis.
Exposure Variable and Predictors
We extracted from the Swiss IBD Cohort Study database demographic variables (age, sex), disease characteristics (symptom duration, EIM, type of IBD, disease activity and extension, familial history of IBD), treatment characteristics, lifestyle factors (tobacco smoke, body mass index), and generic quality of life measures (SF-36).
We used the Montreal classification for localization of intestinal disease at inclusion. In CD, L1 describes ileal disease, L2 colonic involvement, L3 ileocolonic disease, and L4 isolated upper gastrointestinal tract disease. 30 For UC, we categorized the condition into proctitis, left-sided colitis, and pancolitis. Severity and activity of digestive disease was assessed by the gastroenterologist according to the Crohn's Disease Activity Index for patients with CD 31 and the Modified Truelove and Witts Activity Index 32 for patients with UC. In CD, the cutoff for active disease was set at Crohn's Disease Activity Index $150, 33 and for UC, the cutoff for active disease was set at Modified Truelove and Witts Activity Index $10. 34 We used the WHO categorization for the body mass index (BMI).
Statistical Analysis
The statistical analysis was performed using Stata v. 13.1 for Windows (StataCorp., College Station, TX). First, continuous data distribution normality was assessed using normal Q-Q plots. Normally distributed variables were presented as mean 6 SD, whereas nonnormally distributed variables were presented as median and interquartile range. Differences in mean values between two groups were assessed by the Student's t test for normally distributed variables. For nonnormally distributed variables, the Wilcoxon-Mann-Whitney rank-sum test was used to assess differences in distribution between two groups. Categorical variables were presented as raw counts and relative percentages. Differences in repartition of categorical variables among groups were assessed using the chi-squared test, or the Fisher's exact test in case of insufficient sample size. All statistical tests were two sided, and the significance level was set at 0.05. Confounding was a concern in this study because it is known from the literature that IAD is more often associated with CD, with other EIM of IBD and longer disease durations. 8, 9, 35, 36 Because such differences may produce spurious associations, we used multivariate adjustments to overcome such confounding effects. We first examined univariate associations between disease characteristics and presence of IAD using logistic regression. We then performed a multivariable logistic regression to analyze which of the characteristics were independently associated with the presence of IAD.
RESULTS
A total of 2401 patients were included in the study. Patients with indeterminate colitis (n ¼ 48) were excluded, leaving 2353 patients for the analysis (1359 patients with CD and 994 with patients with UC). Forty-four percent of all patients fulfilled our criteria for IAD, of which 42% presented a pure peripheral arthritis. Only 29% of patients with IAD reported ever consulting a rheumatologist for their symptoms (29% versus 7%, P , 0.001). In two-thirds of cases, IAD was corroborated both by patients and gastroenterologists. As expected, patients with IAD were more often on nonsteroidal anti-inflammatory drugs than patients without IAD (8% versus 3%, P , 0.001) and reported lower quality of life (P , 0.001) ( Table 1) .
In univariate analyses, IAD was more frequent in patients with CD than in patients with UC (64% versus 36%, P , 0.001). Furthermore, IAD was more common in women than in men (50% versus 37%, P , 0.001), in older than in younger patients (mean age, 43 versus 38 yr, P , 0.001), and in smokers than in 
DISCUSSION
In this large cohort of patients with IBD, IAD was present in 44% of patients, underscoring that articular involvement is frequent in this population. IAD may sometimes be neglected by specialists, as only one quarter (29%) of these patients reported ever seeing a rheumatologist. Axial involvement was the most common IAD presentation. IAD was more frequent in patients with CD than with UC, in females and in elderly. In patients with UC, IAD was further associated with smoking and overweight.
The prevalence of articular involvement reported in our cohort is higher than described in some other studies 5, 6, [8] [9] [10] 37 but is consistent with what Turkcapar et al 7 described (46%). One possible explanation for the high prevalence of IAD in this study found that the prevalence of IAD doubles after 20 years of IBD, whereas Palm et al 8, 10 described a 3-fold increase after 6 years of disease. Another explanation for the high prevalence of IAD is the preponderance of CD in the Swiss IBD cohort, whereas most other cohorts included more patients with UC, typically less associated with IAD. 5, 8, 10 We considered IAD that occurred at any time point during the course of the disease, as opposed to IAD present only at inclusion, 38 which could have further increased the prevalence of articular manifestations. Finally, it is possible that our definition of IAD overestimates the prevalence of IAD, as it also includes patient-defined articular symptoms, which may overdiagnose IAD by up to 10%, based on our validation study.
In accordance with the literature, 9,10,35 IAD occurs more frequently in patients with CD than in patients with UC in our cohort. We also found that IAD was significantly more common in patients with other EIM, such as cutaneous, ocular, or oral complications. 9, 36 These findings corroborate the hypothesis of similar pathways of the different EIM. 20, 39 Some authors have also described an association between IAD and the localization or the activity of the digestive disease. 9, 10, 36 We did not find any association between the occurrence of IAD and the localization of the intestinal involvement. Nevertheless, we could corroborate a trend to more IADs in patients with more active digestive disease, in particular in patients with CD with pure peripheral arthritis, as classically described. 5 However, associations with disease activity or specific therapies in a cross-sectional study design have to be interpreted with caution, as the use of immunomodulatory therapies may tend to weaken this association (bias towards the null). In UC, tobacco consumption was a risk factor for IAD, which is interesting given the established association between smoking and other inflammatory arthritides such as rheumatoid arthritis, ankylosing spondylitis, and systemic lupus erythematosus. [40] [41] [42] Similarly, higher BMI was associated with UC, which is also an established risk factor for developing other articular diseases, such as psoriatic arthritis or rheumatoid arthritis. Intriguingly, the association with tobacco was not found in patients with CD, reproducing the differential effect of smoking on the intestinal disease in UC and CD. 43, 44 Several mechanisms have been proposed to explain the effect of tobacco, such as modulation of cellular and humoral immunity, effect on gut permeability, colonic mucus, and mucosal blood flow. However, the precise cellular and molecular mechanisms are still unknown. [45] [46] [47] One important finding of our study is that only 29% of patients having IAD ever consulted a rheumatologist for their articular symptoms. Potentially, many of the IAD symptoms are mild and self-limited and thus do not warrant specialized care. However, one cannot exclude some trivialization of the articular complaints by the treating physician confronted with patients with chronic digestive symptoms. Patients with IBD and concomitant IAD may warrant more aggressive therapy, suggesting that physicians following patients with IBD should search for articular manifestations, in particular if other EIM are present.
Strengths of this study are a large multicentric IBD cohort, confirmed by endoscopic and histological findings. Patients were recruited from a wide variety of settings, such as private practices, regional hospitals, and large tertiary centers. We do not believe that selection bias played a major role in the prevalence of IAD, as articular involvement was similar between the different recruitment sources (P ¼ 0.78). The sensitivity analysis restricted to physician-reported arthritis showed similar results, suggesting that our results are not biased by patientreported articular involvement. Some methodological issues of our study should be discussed. Our IAD definition included past articular involvement and may be affected by recall bias. However, potential recall bias is unlikely to be differential between the two groups, as all patients have IBD. Furthermore, we validated our patient questionnaire in a control population and demonstrated a good discrimination between inflammatory articular patterns and noninflammatory arthralgias. Our IAD definition further relies on the diagnosis of arthritis by nonspecialists, which is likely to result in underdiagnosis. In fact, in 35% of our IAD cases, the physician was not aware of the articular involvement. Furthermore, only one-third of these patients ever reported seeing a rheumatologist for a formal diagnosis. However, we believe that by combining patient and physicianreported articular involvement, we obtained a more reliable estimate of IAD prevalence. Another common limitation of cohort studies is missing data. In this cohort, the response rate to the patient questionnaire was of 72%. We do not believe that missingness in this study was differential between patients with or without IAD and is thus unlikely to bias our results in a significant way. We could not assess the temporality of IAD involvement in relation to the course of the digestive disease, thus our results represent a cumulated prevalence of IAD. Finally, anti-tumor necrosis factor and immunomodulatory medications may have influenced the presence of current IAD, as 20% of patients in this analysis were on anti-tumor necrosis factor at inclusion. However, our IAD definition included past arthritis episodes, before immunomodulatory therapies; thus, current medication is unlikely to have biased our overall IAD prevalence.
In conclusion, this study suggests that physicians need to be aware of the various presentations of articular involvement (axial, peripheral, mixed) to make an adequate diagnosis. Gastroenterologists need to identify patients with IBD with concomitant IAD, as these patients may probably need more aggressive management and are more likely to suffer from other extraintestinal complications.
